Abstract
Glucose-dependent insulinotropic polypeptide (GIP) acts as a glucose-dependent growth factor for beta-cells. Here we show that GIP and glucose also act synergistically as anti-apoptotic factors for beta-cells, using the well-differentiated beta-cell line, INS-1. Mitogenic and anti-apoptotic signaling of GIP were dependent upon pleiotropic activation of protein kinase A (PKA)/cAMP regulatory element binder (CREB), mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3-kinase)/PKB signaling modules. The signaling modules activated by GIP were dependent on glucose metabolism and calcium influx and were tightly linked by multiple activating and inhibiting cross-talk. These interactions included: (i) a central role of tyrosine phosphorylation for stimulation of PKA/CREB, MAPK and PI3-kinase/PKB, (ii) inhibition of PKA/CREB by the MAPK pathway at the level of MAPK kinase-1 or downstream, (iii) activation of MAPK signaling by PI3-kinase and PKA at the level of extracellular-signal regulated kinase 1/2 or upstream, and (iv) activation of PKB by MAPK and PKA signaling at the level of PKB or upstream. Furthermore, we demonstrated inhibition of CREB signaling by Ca(2+)/calmodulin kinase I/IV. These results indicated that GIP acts as a mitogenic and anti-apoptotic factor for beta-cells by pleiotropic activation of tightly linked signaling pathways in beta-cells.
MeSH Terms
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/analogs & derivatives,pharmacology
Alloxan/pharmacology
Androstadienes/pharmacology
Apoptosis/drug effects
Arginase/genetics
B-Lymphocytes/metabolism
Benzylamines/pharmacology
Calcium/metabolism
Calcium-Calmodulin-Dependent Protein Kinases/antagonists & inhibitors
Cell Line
Chelating Agents/pharmacology
Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors
Deoxyglucose/pharmacology
Egtazic Acid/pharmacology
Enzyme Inhibitors/pharmacology
Flavonoids/pharmacology
Gastric Inhibitory Polypeptide/pharmacology
Genistein/pharmacology
Glucokinase/antagonists & inhibitors
Glucose/metabolism
Humans
Indoles/pharmacology
Isoquinolines/pharmacology
MAP Kinase Kinase 1
MAP Kinase Signaling System/drug effects
Maleimides/pharmacology
Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors
Mitosis/drug effects
Phosphoinositide-3 Kinase Inhibitors
Plasmids
Protein Kinase C/antagonists & inhibitors
Protein Serine-Threonine Kinases/antagonists & inhibitors
Protein-Tyrosine Kinases/antagonists & inhibitors
Signal Transduction/drug effects
Sulfonamides/pharmacology
Wortmannin
Chemicals
Androstadienes
Benzylamines
Chelating Agents
Enzyme Inhibitors
Flavonoids
Indoles
Isoquinolines
Maleimides
Phosphoinositide-3 Kinase Inhibitors
Sulfonamides
KN 93
Egtazic Acid
Gastric Inhibitory Polypeptide
KN 62
Alloxan
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
Deoxyglucose
Genistein
Glucokinase
Protein-Tyrosine Kinases
Protein Serine-Threonine Kinases
Cyclic AMP-Dependent Protein Kinases
Protein Kinase C
Calcium-Calmodulin-Dependent Protein Kinases
MAP Kinase Kinase 1
MAP2K1 protein, human
Mitogen-Activated Protein Kinase Kinases
Arginase
Glucose
bisindolylmaleimide I
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
Calcium
Wortmannin
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Trümper A
Department of Internal Medicine, Division of Gastroenterology and Endocrinology, Philipps-University, Baldingerstrasse, D-35033 Marburg, Germany.
Trümper K
Hörsch D